PALO ALTO, Calif., Oct. 11 (UPI) -- CV Therapeutics said Wednesday it planned to end its co-promotion of Aceon with Solvay Pharmaceuticals so it could focus on Ranexa.
CV said it does not expect further revenues from Aceon, an angiotensin converting enzyme inhibitor for treating hypertension. CV added that there are no financial commitments for it or Solvay related to the termination of the co-promotion agreement.
"We are excited to focus our promotional efforts on Ranexa, as we continue to see growing interest in the cardiology community," said Dr. Louis G. Lange, CV's chairman and chief executive officer.
Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other medications.
CV said it will conclude its promotion of Aceon over the next several weeks.
